Hirata Akihiro, Itatsu Keita, Fukaya Masahide, Ebata Tomoki, Yokoyama Yukihiro, Tsunoda Nobuyuki, Igami Tsuyoshi, Sugawara Gen, Uehara Keisuke, Yoshioka Yuichiro, Usui Hiroaki, Nagino Masato
Division of Surgical Oncology, Dept. of Surgery, Nagoya University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2013 Apr;40(4):519-22.
S-1 adjuvant chemotherapy following radical surgery has been the standard therapy for the pStage II/III gastric cancer in Japan. However, there are few reports regarding treatment for gastric cancer recurrence during S-1 therapy. Here, we present a case of recurrent gastric cancer during S-1 adjuvant therapy that showed partial response to CDDP + capecitabine therapy. A 72-year-old man was diagnosed as having gastric cancer. We performed a distal gastrectomy+D2 dissection, with Roux-en Y reconstruction. The patient was treated with S-1 for adjuvant chemotherapy. Six months after operation, multiple mediastinal lymph node recurrence developed. CDDP + CPT-11 was applied for two courses as first-line treatment for the recurrence. However, the disease progressed with worsening mediastinal lymph node metastases (progressive disease). After two courses of CDDP + capecitabine as second-line chemotherapy, the recurrence site became smaller. After five courses, partial response (PR) had been achieved. Two years and five months after gastrectomy, capecitabine monotherapy was applied as third-line chemotherapy.